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Studies related to bone mass in patients with cystic fibrosis 
Eva Gronowitz 
Department of Pediatrics, Institute for the Health of Women and Children, 
Sahlgrenska Academy, Göteborg University, Göteborg, Sweden 
Cystic fibrosis is the most common genetic disease that causes respiratory failure and early 
death. The lifespan of these patients has gradually increased due to improved general 
treatment, but concurrent with this, new complications have emerged, and changes in bone 
mineral density (BMD) have been stressed as a major problem. The aim of this work was to 
study BMD in normal growing patients with cystic fibrosis (CF) and relate to factors of 
importance for bone mass, like vitamin D, calcium and parathyroid hormone. 
Seventy consecutive patients, aged 6-49 years with CF were investigated with dual energy X-
ray absorptiometry (DXA) of the lumbar spine (LS) and the femoral neck (FN) and 54 of 
them were followed prospectively for two years. The results were related to clinical, 
anthropometric and biochemical data. The average z-score of BMD was decreased in the LS 
in 40% of children and adults. Osteoporosis was rare. BMD increased at a normal rate during 
the two years, and correlated to body weight and lung function. Intact parathyroid hormone 
was positively correlated to the increase of BMD in both LS and FN during childhood. There 
were no correlations to serum levels of vitamin D and calcium but patients with pathological 
blood sedimentation rate and serum levels of immunoglobulin G had significantly lower 
BMD than those with normal values. 
In fourteen young men with CF and 42 healthy controls the DXA investigations were 
complemented with peripheral quantitative computerized tomography (pQCT). No differences 
in bone parameters between the two groups were obtained but CF patients, chronically 
colonized with Pseudomonas areuginosci, had significantly lower trabecular BMD than not 
colonized patients. 
Low serum levels of vitamin D despite regular supplementation has frequently been reported 
in CF. The fact that Sweden is located on a high latitude (Göteborg, N58), motivated us to 
study if these serum levels would improve during the dark season by regular ultraviolet B 
(UVB) radiation. An intervention study was performed for 6 months and a significant increase 
in the serum level of vitamin D was obtained in the UVB group. The osteocalcin levels 
decreased reflecting a decreased bone loss but the PTH values did not decrease after the 
treatment as expected. 
Conclusions: Although patients with CF had normal anthropometry, still 40 % had decreased 
BMD (z-score less than -1SD) in the cross sectional study. The influence of CF on BMD may 
start early in life since the growth rate of BMD during 2 years was normal and did not differ 
from that in healthy controls. The studies imply that low BMD in CF is multifactorial and 
associated with infection and nutritional parameters. We suggest that our result of normal 
BMD compared to the general literature might be related to several factors in our treatment 
program, including regular physical activity, short courses of high doses of antibiotics at very 
mild symptoms and a good nutritional support. UVB radiation would be a good 
supplementary treatment, but has practical difficulties on a routine basis . 
Key words: DXA, infection, lung function, parathyroid hormone, physical activity, vitamin D, 
pQCT, UVB. 
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Studies related to bone mass in patients with cystic fibrosis 
Eva Gronowitz 
Department of Pediatrics, Institute for the Health of Women and Children, 
Sahlgrenska Academy, Göteborg University, Göteborg, Sweden 
Cystic fibrosis is the most common genetic disease that causes respiratory failure and early 
death. The lifespan of these patients has gradually increased due to improved general 
treatment, but concurrent with this, new complications have emerged, and changes in bone 
mineral density (BMD) have been stressed as a major problem. The aim of this work was 
to study BMD in normal growing patients with cystic fibrosis (CF) and relate to factors of 
importance for bone mass, like vitamin D, calcium and parathyroid hormone. 
Seventy consecutive patients, aged 6-49 years with CF were investigated with dual energy 
X-ray absorptiometry (DXA) of the lumbar spine (LS) and the femoral neck (FN) and 54 
of them were followed prospectively for two years. The results were related to clinical, 
anthropometric and biochemical data. The average z-score of BMD was decreased in the 
LS in 40% of children and adults. Osteoporosis was rare. BMD increased at a normal rate 
during the two years, and correlated to body weight and lung function. Intact parathyroid 
hormone was positively correlated to the increase of BMD in both LS and FN during 
childhood. There were no correlations to serum levels of vitamin D and calcium but 
patients with pathological blood sedimentation rate and serum levels of immunoglobulin G 
had significantly lower BMD than those with normal values. 
In fourteen young men with CF and 42 healthy controls the DXA investigations were 
complemented with peripheral quantitative computerized tomography (pQCT). No 
differences in bone parameters between the two groups were obtained but CF patients, 
chronically colonized with Pseudomonas areuginosa, had significantly lower trabecular 
BMD than not colonized patients. 
Low serum levels of vitamin D despite regular supplementation has frequently been 
reported in CF. The fact that Sweden is located on a high latitude (Göteborg, N58), 
motivated us to study if these serum levels would improve during the dark season by 
regular ultraviolet B (UVB) radiation. An intervention study was performed for 6 months 
and a significant increase in the serum level of vitamin D was obtained in the UVB group. 
The osteocalcin levels decreased reflecting a decreased bone loss but the PTH values did 
not decrease after the treatment as expected. 
Conclusions: Although patients with CF had normal anthropometry, still 40 % had 
decreased BMD (z-score less than -1SD) in the cross sectional study. The influence of CF 
on BMD may start early in life since the growth rate of BMD during 2 years was normal. 
The studies imply that low BMD in CF is multifactorial and associated with infection and 
nutritional parameters. We suggest that our result of normal BMD compared to the general 
literature might be related to several factors in our treatment program, including regular 
physical activity, short courses of high doses of antibiotics at very mild symptoms and a 
good nutritional support. UVB radiation would be a good supplementary treatment, but has 
practical difficulties on a routine basis. 
Key words: DXA, infection, lung function, parathyroid hormone, physical activity, vitamin 
D, pQCT, UVB. 
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Abbrevations 
BMC bone mineral content 
BMI body mass index 
BMD bone mineral density 
Ca calcium 
CFTR cystic fibrosis transmembrane conductance regulator 
CF cystic fibrosis 
DXA dual energy X-ray absorptiometry 
EFA essential fatty acids 
EF AD essential fatty acid deficiency 
FM fat mass 
FN femoral neck 
FEV lo forced expiratory volume in one second 
FVC forced vital capacity 
GOOD Gothenburg Osteoporosis and Obesity Determinants study 
iPTH intact parathyroid hormone 
ivAC intravenous antibiotic courses 
LBM lean body mass 
LS lumbar spine 
MED minimal erythemal dose 
NNR Nordic Nutrition Recommendations 
P phosphate 
PI pancreatic insufficient / insufficiency 
pQCT peripheral quantitative computerized tomography 
URSO ursodeoxycholic acid 
PS pancreatic sufficient / sufficiency 
WC working capacity 
25(OH)D 25-hydroxy vitamin D 
1.25(01 l)2D 1,25-dihydroxy vitamin D 
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Cystic fibrosis (CF) 
CF is an autosomal recessive inherited disease that mainly affects the respiratory, digestive 
and reproductive systems. Currently, there is no cure for CF, but improved therapy has 
changed CF from a disease characterized by death in early childhood to a chronic illness. 
The median life expectancy for a person with CF is now over 40 years (Frederiksen et al. 
1996, Hodson et al. 1998). Only thirty years ago, a CF patient was not expected to reach 
adulthood. One in 2 500 - 3 400 Caucasian babies has the disorder (Kosorok et al. 1996), 
making CF one of the most common lethal genetic diseases in Caucasians. It is less 
common in Scandinavia, the incidence in Sweden being about 1/6000 (Lannefors et al. 
2002, Selander et al. 1962). 
The CF gene was localized to chromosome 7 in 1985, and in 1989 the defective gene was 
identified (Kerem et al. 1989, Riordan et al. 1989, Rommens et al. 1989). The CF gene 
encodes for a membrane protein named cystic fibrosis transmembrane conductance 
regulator (CFTR). It consists of 1480 amino acids and is a chloride channel found in 
epithelial tissues. CFTR also has regulatory functions for other ion channels in the cell 
membrane and probably other, as yet, not identified functions. Today more than 1360 
different mutations have been identified within the gene (cystic fibrosis genetic analysis 
consortium). The most common mutation is a deletion of phenylalanine at position 508, 
named AF508, and about 66 % of the Swedish CF population have this mutation, 394delTT 
is the second most common severe mutation typical for Scandinavia and found in 7% of 
the alleles (Strandvik et al. 2001). 
Many different organs and systems are affected in CF. The defective chloride excretion 
and an increased sodium absorption contribute to more concentrated secretary products. 
The glands further produce mucus with changed chemical structure and properties; 
altogether causing sticky mucus that can lead to obstructions in the respiratory, digestive 
and genital systems (for review see Hodson et al. 1995) (fig.l). 
In the respiratory system, the abnormal mucus obstructs airways and also creates 
conditions that contribute to chronic bacterial colonization causing repeated infections in 
the airways. These usually progress and destroy the lungs. Similar sticky mucus causes 
chronic sinusitis. Nasal polyps are common. 
In the digestive system, the abnormal mucus can obstruct ducts in many different organs. 
In the liver, plugs in the biliary system can impede bile flow and influence liver and biliary 
function. 
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The changes in the ducts of the pancreas hinder the delivery of important digestive 
enzymes to the bowel. This makes it difficult for persons with CF to effectively digest food 
and absorb nutrients. A defective bicarbonate excretion in the duodenum and pancreas 
further contribute to digestive problems. Therefore, people with CF need to have 
supplementations of enzymes and vitamins. 
In newborns, tenacious meconium may cause an obstruction of the gut which often 
requires surgery. Similar events occur in 10 % of adult patients with CF. Further, the 
reproductive tract is affected in 95% of males causing infertility due to atresia of the vas 
deference and atrophy of vesicae seminalis. On occasion, women may also be infertile 
associated with the abnormal mucus. 
Modified from Cystisk fibrös, MFR. Illustration: Annika Röhl 
Sinusitis : Chronic sinusitis i: 
common complication of CF 
Sweat: Patients with CF have 
an increased amount of 
sodium and chloride (salt) in 
their sweat. 
Small Intestine : Obstruction of 
the gut by sticky stool in 
newborns, but also occurring in 
children, adolescents and adults 
Reproductive tract : Atrophy of vas 
deference and vesicae seminalis 
causes 95 % of males infertility. 
Airways: Clogging and infection of 
bronchial passages impedes breathing . 
The infections progressively destroy 
the lungs. 
Liver: Plugging of bile 
ducts impedes digestion 
and liver function. 
Pancreas : Occlusion of ducts 
prevents the pancreas from 
delivering critical digestive 
enzymes to the bowel in 85 ( 
patients. 
: kidney stones are an 
xeasingly common complication 
Fig 1. Organs affected by the cystic fibrosis disease 
Essential fatty acid deficiency (EFAD) is also common among patients with CF. It is 
shown to be associated with an abnormal release of arachidonic acid and consequently low 
levels of linoleic acid (Carlstedt-Duke et al. 1986, Levistre et al. 1993, Miele et al. 1997). 
Many of these patients are in good nutritional status treated with modern enzyme 
supplementation, so there is now a general agreement that the EFAD cannot be explained 
as a consequence of malabsorption (Strandvik 2004). Most of our patients are 
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recommended extra vegetable oil as an EFA supplementation in their diet; the indication is 
based on their serum phospholipid fatty acid pattern. 
There are variations in disease severity even among individuals with the same genotype. It 
has therefore been suggested that CFTR genotype alone does not determine CF phenotype. 
The presence of genetic modifiers or modifying genes may play a significant role in 
influencing the CF phenotype (Salvatore et al. 2002). 
Some patients may have mild symptoms during infancy and childhood and escape 
diagnosis until adulthood. On the other hand some problems mainly occur in adolescence 
or adulthood and since patients now have an increased longevity these problems add to the 
symptomatology. Such problems are diabetes mellitus and low bone mineral density 
(BMD), the former being a problem in 20-40 % and the latter in 40-75% of the patients 
with implications for patients' quality of life (Aris et al. 1998 & 2004, Conway et al. 2000, 
Donovan et al. 1998, Haworth et al. 1999, Mischler et al. 1979, Moran et al. 2000). 
Bone mass 
Structure and' function of bone 
There are two types of bone tissue; cortical or compact bone, and trabecular or cancellous 
bone. In an adult with total body content of calcium of approximately 1 kg, 80% of the 
skeletal mass is cortical. Cortical bone serves as a protective covering and surrounds 
trabecular bone. The ratio of cortical and trabecular bone varies throughout the bones of 
the body. Cortical bone is predominantly found in the limbs, and is responsible for the 
strength of the skeleton. Cortical bone mainly consists of protein (collagen) and calcium, 
phosphate and salts, and has three layers, the periostal envelope which is the outer surface 
of the bone, the intracortical envelope which constitutes the next layer down and the 
endostal envelope, the layer next to the bone marrow cavity (Loud 2002). 
The bones of the axial skeleton, which include the rib cage, the backbone and the skull, 
have a higher proportion of trabecular bone than the bones in the appendicular skeleton. 
The cancellous bone comprises trabecular plates and rods of tissue, which interconnect 
with each other and with the inner aspect of the cortex. It provides only a small part of 
skeletal strength compared to that of cortical bone, but has a very important part in bone 
metabolism (for review see Kanis 1994). The main functions of the skeleton are to be a 
protection of internal organs, reservoir for calcium and phosphorus and harbour the bone 
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marrow, the site for haematopoesis. It also provides a framework that supports the body; 
the muscles that are attached to the bones move the skeleton. 
Bone modeling, growth and remodeling 
Long bones of children increase in length and diameter by a process called modeling. Bone 
modeling represents an adaptive process of general and continues growth and reshaping of 
bone governed by the activities of osteoblasts and osteoclasts until the adult bone structure 
is attained (Seifert et al. 1997). This growth requires that bone cells function normally. 
During this process 100% of bone surfaces are active until proper bone size is achieved. 
Bone modeling is distinct from bone remodeling, which describes the local, coupled 
process of bone resorption and formation that maintains skeletal mass and morphology 
continuously during life. 
The two cells responsible for bone turnover are called osteoblasts and osteoclasts. The 
continual removal of bone (bone resorption) by osteoclasts and the following synthesis of 
new bone matrix and its subsequent mineralization by osteoblasts (bone formation) is a 
process called bone remodelling (Eriksen 1986). Collagen provides the basic bone 
structure into which the minerals (calcium phosphate salt) are deposited and mineralised. 
This bone remodeling occurs repeatedly as bones undergo a constant process of 
reformation. 
In the long bones the growth in length continues from birth through adolescence in the 
metaphysial part of the bone, located between the diaphysis (shaft) and epiphysis (head). 
Elongation is achieved by the activity of the two cartilaginous growth plates. Rapidly 
growing trabecular bone is underlying the base of the plates. The thickness of the 
epiphyseal plates gradually decreases and when this bone lengthening process ends, the 
plates disappear and the head and shaft are united. In humans, different bones stop 
lengthening at different ages. 
The diaphysis consists of compact bone enclosing the medullary cavity. Another process 
called appositional growth causes bones to get wider and increase in circumference. This 
happens due to bone tissue being deposited under the bone's covering, called the 
periosteum. There is a very delicate balance between the growth in length and the growth 
in diameter so that we have bones that are proportional in size. These processes are also 
coordinated with bone destruction as the marrow cavity has to be of proportional size too 
(Prie set al. 1994) 
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The metabolic activity of bone is predominantly a surface-based phenomenon. Although 
cortical bone compromises most of the total skeletal tissue, the surfaces available in 
cortical bone are much lower than those of cancellous tissue. Indeed the surface /volume 
ratio of trabecular bone is 8- 10 fold greater than that of cortical bone. Since the bone 
remodeling activity is greater in cancellous bone, abnormal bone remodeling is expressed 
earlier at these sites, as is the case in osteoporosis. 
The bone mass continues to increase and in early adulthood, it achieves a maximum value, 
known as the peak bone mass. Growth is most prominent in the first few years after birth 
and thereafter at the adolescent growth spurt. This is one reason why nutritional factors are 
particularly important during these periods of skeletal development. At these times the 
demands for calcium are particularly high although less marked than might be suggested 
by the increase in height. This is because remodeling activity also increases, which in turn 
increases cortical porosity and the resorption space. Thus, bone mineral content (BMC) 
increases less than expected for the increase in skeletal size. The desired length of the bone 
is obtained but the bone is still very weak because of lack of calcium, and a new phase of 
hardening and calcification begins. This phase comprises the expected increase in bone 
mineral related to a decrease in bone turnover and changes in cortical width. The phase 
between the cessation of longitudinal skeletal growth and the attainment of peak bone mass 
has been termed consolidation (Loud KJ et al. 2002). The extent and the duration of 
consolidation are not well documented by longitudinal studies. Consolidation occurs more 
rapidly at some sights than at others and varies between sexes so that in adulthood, skeletal 
mass is 10-50% higher in men than in women depending on the skeletal site measured. 
Most authors suggest that peak bone mass is reached before the end of the second decade 
(Bonjour et al. 1991, Theintz et al. 1992). Other studies suggest that consolidation 
continues until the third decade of life (Recker et al. 1992). The femoral neck (FN) seems 
to reach its peak earlier than the lumbar spine (LS) (Heaney et al. 2000, Theintz et al. 
1992). It is an advantage to reach as high a peak bone mass as possible since this lowers 
the later risk of osteoporosis. Bone mass remains stable at this level from about 25 to 35 
years of age; the rate of bone formation is now exactly balanced by the rate of resorption. 
From that age on, the balance shifts to favour resorption and the skeleton begins to lose 
bone mass. After 35 - 40 years of age bone loss occurs in both sexes, but for women it 
accelerates during the first menopausal decade due to the reduced secretion of oestrogen. 
Oestrogen inhibits the action of the osteoclasts. When there is a lack of oestrogen there is 
an increase in osteoclast activation, so bone is resorbed faster than it is rebuilt leading to a 
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net bone resorption. This effect explains why osteoporosis is more common in women than 
in men but, although there is no accelerated phase of bone loss, men still have age-related 
bone loss (fig. 2) (Kanis 1994). 
Peak bone mass Female 
50 
Age (yrs) 
Fig 2. Change in bone mass during lifetime 
There are several biochemical markers that provide information about the dynamics of the 
bone turnover. Some are; osteocalcin and carboxy-terminal propeptide of type I 
procollagen (PICP) as markers of bone formation. Serum cross-linked carboxy-terminal 
telopeptide of type I collagen (ICTP) and urine crosslinked N-telopeptide of type I 
collagen (NTX) are breakdown products in bone collagen reflecting bone resorption. 
Calcium homeostasis 
Calcium is important for bone mass but also has important roles in intracellular processes. 
The body calcium is derived from dietary calcium. The recommended daily dose varies 
with age; it is 400-600 mg for children and 800 mg/day for adults and is increased during 
adolescence and pregnancy (1200 mg). Once it is absorbed it can be stored in the bone or 
lost in the urine depending on if there is more calcium than needed for intra- and extra 
cellular processes. Its regulation is therefore of vital importance. Several hormones 
regulate calcium metabolism and can be subdivided into "controlling" and "influencing" 
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hormones. The "controlling" hormones are parathyroid hormone (PTH), calcitonin (CT) 
and vitamin D metabolites. Exchange of calcium in the extra cellular fluid occurs in bone, 
gut and kidney. The net balance for calcium equals the net absorption minus the losses of 
calcium in faeces and urine, which in healthy adults are negligible. In patients with 
steatorrhoea, calcium is usually lost in faeces esterfied with fatty acids as calcium soaps. 
At low calcium levels PTH increases renal tubular reabsorption of calcium and the 
resorption of bone. CT inhibits bone resorption and vitamin D increases intestinal 
absorption of calcium. The precise role of vitamin D in augmenting bone resorption and 
mineralization in vivo is not clear (fig.3) (for review see Kanis 1994). The main 
"influencing" hormones are thyroid and growth hormones and adrenal and gonadal 
steroids, which all have important effects on calcium metabolism, but whose secretion is 
determined primarily by factors other than changes in plasma calcium. 
Fig 3. Calcium homeostasis 
Vitamin D 
Kidney 
Vitamin D 
i7 
Farmn.tîan 
Resorption 
Vitamin D 
Bone 
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Parathyroid hormone (PTH) 
This hormone is secreted from the cells of the parathyroid glands and is an important 
regulator of calcium and phosphate in the extra cellular fluid. It is released by low extra 
cellular concentrations of free calcium. PTH stimulates the osteoclasts to reabsorb bone 
mineral and to set calcium free into the blood. It also enhances the absorption of calcium 
from the small intestine to increase the blood levels of calcium. PTH stimulates this 
process indirectly by stimulating production of the active form of vitamin D in the kidney. 
Further, PTH suppresses the loss of calcium in urine by stimulating the tubular 
reabsorption of calcium, and also stimulates the loss of phosphate in the urine (fig. 3). 
Increased secretion of PTH is seen in primary hyperparathyroidism and is a result of a 
disease in the parathyroid glands, i.e. in cancer. The cause of secondary hyper­
parathyroidism is a disease in another organ than the parathyroid glands, for example if the 
kidneys are unable to reabsorb calcium, or if the intake of calcium is insufficient. The PTH 
metabolism is still not fully explained and in recent years different studies in animal and 
humans have demonstrated that intermittent PTH administration induces anabolic effects 
on bone by enhancing bone mass that increases the strength of the bones (Aleksyniene et 
al. 2004). 
Calcitonin 
is a hormone that is secreted from the cells in the thyroid glands in response to 
hypercalcemia, and functions by reducing blood calcium levels. It suppresses the 
reabsorption of calcium in the kidney and enhances the excretion of calcium into urine. It 
inhibits the action of the osteoclasts so that resorption is suppressed (fig.3). 
Vitamin D 
The main source of vitamin D is vitamin D3 (cholecalciferol), formed in the skin from 7-
dehydrocholesterol by the action of ultraviolet radiation with wavelengths 290-315 nm 
(UVB) (Lucas et al. 2002, Preece et al. 1975). Ninety to 100% of vitamin D in most 
humans comes from exposure of sunlight (Holick MF 2002). Vitamin D in food, mainly 
vitamin D2 (ergocalciferol) from fortification, is considered to be of minor importance. 
Vitamin D2 and D3 are comparable in their metabolism and action. They are converted in 
the liver to 25-hydroxyvitamin D (calcidiol) (25(OH) D) and further to the active form of 
vitamin D, 1,25 dihydroxyvitamin D (calcitriol) (l,25(OH)2D) in the kidneys (fig. 4). It 
affects the intestinal absorption of calcium and phosphate and also increases the absorption 
16 
of calcium from bone. A lack of this vitamin is associated with defective mineralization of 
bone (Holick MF 2002 & 2003, Preece et al. 1975). Other tissues as colon, prostate, breast 
and skin can also produce calcitriol. The kidney acts as an endocrine organ to produce 
l,25(OH2)D for the purpose of regulating calcium, phosphate and bone metabolism. In 
other tissues the production of l,25(OH)2D locally in the cells may be of importance for 
maintaining normal cell growth and possibly preventing carcinogenesis of these tissues 
(Holick MF 2002 & 2003, Lehmann B et al. 2002). 
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Fig 4 Vitamin D metabolism 
Osteomalacia 
Osteomalacia means "soft bones". Osteoid is the bone protein matrix, composed primarily 
of type 1 collagen. When there is insufficient mineral or an osteoblast dysfunction, the 
osteoid does not mineralize properly. Many cases of osteomalacia are related to 
abnormalities in vitamin D metabolism. 
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When the newly formed bone of the growth plate does not mineralize, the growth plate 
becomes wide and irregular. This results in the clinical diagnosis of rickets, and is seen 
only in children because adults no longer have growth plates. When the remodeled bone 
does not mineralize, osteomalacia occurs. 
Osteoporosis 
Osteoporosis is characterized by the loss of bone and by microarchitectural deterioration of 
bone tissue (fig. 5), which leads to bone fragility with a consequent increase in fracture 
risk. Osteoporosis has been classified into two categories; primary and secondary 
osteoporosis. Primary osteoporosis has been divided into two types. Type I refers to 
postmenopausal osteoporosis (mainly trabecular loss) in women and is related to oestrogen 
deficiency. Type II occurs in both genders, and refers to age-related decline in density in 
both cortical and trabecular bones. Secondary osteoporosis occurs when a causative factor 
or illness can be identified. 
Fig 5. Normal (left) and osteoporotic (right) trabechular bone 
http://www.medes.fr/Eaisto/Osteoporosis/Ovemew.html 
Classification of bone mass 
A generally accepted classification of bone mass in women based on bone densitometry 
measurements with dual energy x-ray absoptiometry (DXA) was made by WHO (1994). 
T-score is the number of standard deviations from the mean BMD value of a healthy 25-
year-old woman. 
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Normal bone mass: 
Low bone mass (osteopenia): 
Osteoporosis: 
Severe osteoporosis: 
T-score BMD better than -1 SD. 
T-score BMD between -1 and -2.5 SD 
T-score BMD less than -2.5 SD 
T- score > 2.5 SD below the mean of young adults, 
and the presence of one or more fragility fractures. 
Z-score is the number of standard deviations from the mean BMD value of healthy age-
and gender- matched controls. 
The bone mass is expressed in conventional terms as BMC (g) which is uncorrected for 
bone size. BMD (g/cm2) is corrected for length and bone width. Both BMD and BMC are 
influenced by bone size and may underestimate the bone mineral properties in smaller 
individuals. To compensate these differences it is possible to measure bone mineral 
apparent density, BMAD (g/cm3), which is corrected for length, width and depth of bone, a 
measurement that minimizes the effects of bone size on BMD. 
CF and bone mineral density. 
The life expectancy of patients with CF has increased dramatically over the past few 
decades. As the population of CF grow old, complications like diabetes, liver disease and 
osteoporosis are emerging. Especially, diabetes and osteoporosis were seldom seen in 
previous years. CF related bone diseases are becoming increasingly recognized as a 
clinical complication of CF. It was first described in 1979 by Michler et al. and Hahn et 
al., respectively. Patients with CF have several of the risk factors that have been linked to 
decreased BMD (fig. 6). 
Osteopenia and osteoporosis are common in patients with CF and considered to be 
associated with poor general status, especially in older patients with low body mass index 
(BMI) (Alis et al. 1998 & 2004, Bachrach et al. 1994, Bhudhikanok et al. 1996, Conway et 
al. 2000, Elkin et al. 2001, Fok et al. 2002, Flohr et al. 2002, Gibbens et al. 1988, Haworth 
et al. 1999, Lambert 2000, Rossini et al 2004). A few papers have shown normal BMC and 
BMD in CF patients (Hardin et al. 2001, Salamoni et al. 1996, Sood et al. 2001). Hardin 
showed that there was no difference in whole body or regional BMD between adult CF 
patients and similar stunted controls but not in relation to normally growing controls. In 14 
well nourished CF patients, Salamoni et al. (1996) showed that BMC of the total body and 
LS did not differ from those in age and nutritionally matched controls. 
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Fig 6. Risk factors in patients with CF that effect bone mineral density (BMD). 
In many reports CF patients are smaller than age- matched controls, which potentially 
could bias the results of BMC and BMD. However, Shane et al. (1996) and Bhudikanok et 
al. (1996) also found low BMAD in their patients with CF confirming that the low BMD 
was not due to smaller body size in the CF patients. Pancreatic insufficiency (PI), present 
in 80-85% of the patients, may lead to impaired absorption of calcium, fat and vitamin D 
resulting in low body weight. Low BMD has been reported in both pancreatic sufficient 
(PS) and insufficient patients with CF (Haworth et al. 2002). 
Many studies have found low 25(OH)D levels in patients with CF (Aris et al. 2002, 
Donovan et al. 1998, Elkin et al. 2001, Feranchak et al. 1999, Haworth et al. 1999, 
Henderson et al. 1997, Lark et al. 2001, Reiter et al. 1985) despite supplementation with 
oral vitamin D. Low levels can occur due to malabsorption, reduced sunlight exposure or 
possibly accelerated 25(OH)D catabolism. These results indicate that vitamin D/calcium 
dependent mechanisms are very likely to contribute to low BMD in CF. Lark et al. (2001) 
reported that patients with CF absorbed less than 50% of a test dose of oral ergocalciferol 
as compared to controls. The calcidiol levels did not rise in serum in the CF patients, as 
opposed to the rise observed in the controls. Reduced calcium absorption and an increased 
fecal loss of calcium may also occur in CF (Aris 1999, Schultze et al. 2003 & 2004). 
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The chronic inflammation present in patients with CF might also contribute to osteopenia. 
Acute lung infection in CF is associated with an increase in the osteoclast-stimulatory 
inflammatory cytokines, IL-6, IL-1 and TNFa, and is concomitant with an increase of 
biochemical markers of bone resorption, like NTX and deoxypyridinoline as well as a 
reduction in the bone formation marker, osteocalcin (Aris et al. 2000, Conway et al. 2001, 
Haworth et al. 2004, lonescu et al. 2000, Lambert 2000). Furthermore, physical activity 
has been shown to be beneficial, while inactivity may hasten bone loss (Aris et al. 2004, 
Frangiolas et al. 2003, Marcus 2001, Elkin et al. 2001, Gibbens et al. 1988, Haworth et al. 
1999). 
Many CF patients also have a delayed puberty, low levels of serum testosterone in the 
males and abnormal periods in the females have been reported (Aris et al. 1998, Bachrach 
et al. 1994, Bhudikanok et al. 1996, Leifke et al. 2003, Ujhelyi et al. 2004). An inadequate 
energy intake may delay puberty, a time when a considerable bone growth occurs. 
The use of corticosteroids, mandatory after lung transplantation, is another identified risk 
factor for low BMD. (Aris et al. 1998, Bhudikanok et al. 1996, Shane et al. 1996, Ott 
1998). 
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Aims of the study 
The aims of the study were 
• to investigate the prevalence of low BMD in patients with CF in Western Sweden 
(paper I,II). 
• to elucidate clinical and biochemical data as risk factors in CF associated deficits 
of mineralization, and if these factors differed between children and adults (paper 
Ml).  
• to elucidate if the disturbances of the BMD in CF were progressive (paper II) 
• to elucidate if young men with CF who had reached their final height had normal 
bone mass (paper III). 
• to elucidate if the serum levels of vitamin D would be improved by regular UVB 
radiation (paper IV). 
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Patients and Methods 
Design 
Study i is a cross-sectional study of 70 consecutive patients with CF who regularly 
attended the West Swedish CF Center in Göteborg (paper I). 
Study 2 is a two-year prospective study in 54 patients with CF who regularly attended the 
West Swedish CF Center in Göteborg (paper II). 
Study 3 is a cross-sectional study of 14 young men with CF and 42 healthy controls (paper 
III).' 
Study 4 is an experimental study of the influence of UVB radiation on serum levels of 
vitamin D in 30 patients with CF. Fifteen patients were in the intervention group and 15 
patients served as gender and age matched controls (paper IV). 
Study population 
Clinical data of the patients are depicted in table 1. All patients in study II were included in 
study I. Exclusion criteria for study I and II were age < 6 yrs, for study III age < 18yrs > 25 
yrs and study IV < lOyrs. In study I, II and IV pregnant, transplanted or patients on the 
waiting list for transplantation were excluded. In study IV no pancreatic sufficient (PS) 
patients were included. 
The CF diagnosis was verified by pathological sweat test (CI >60 mmol/1). A ll patients 
were on their basic treatment including vitamin supplementations, as vitamin D and oral 
mucus dissolving therapy (bromhexine) and inhalation of broncholytics (salbutamol and 
saline or N-acetylcysteine). All patients had pulmonary symptoms and most of them were 
physically active as a part of the physiotherapeutic regimen (Blomquist et al. 1986, 
Lannefors et al. 2004). 
Pancreatic insufficiency (PI) was revealed by depletion of pancreatic enzymes in duodenal 
secretion after stimulation with cholecystokinin and secretin or by abnormal fecal elastase. 
Chronic colonization with Pseudomonas aeruginosa and/or Stenotrophomonas 
maltophilia, was determined by repeatedly positive growth of the bacteriae in sputum for 
>6 months and/or increased serum titres against Pseudomonas exotoxin A (Ericsson-
Hollsing et al. 1987). 
The Ethical Committee of Göteborg University approved the studies and informed consent 
was obtained from patients and parents. 
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Table 1: Clinical data in the patients with CF. Figures refer to number of patients 
Study I Study II Study III* Study IV 
n=70 n=54 n=14 n=30 
(30>20yrs) (19>20yrs) (18-25yrs) (22>20yrs) 
Age (yrs) (median (range)) 17.5 (6-49) 17 (6-33) 21.6(18-25) 17 (10-40) 
Sex (M/F) 34/36 25/29 14/0 16/14 
Pancreatic sufficiency 10 4 3 0 
Homozygotes dF508 37 33 10 21 
Heterozygotes dF508 22 17 3 8 
Other mutations 11 4 1 1 
Oral steroid treatment 1 1 0 0 
Inhaled steroid treatment 4 4 0 0 
URSO treatment for liver disease 15 15 2 10 
CF related diabetes mellitus 4 3 2 6 
Chronic Pseudomonas colonisation 41 33 7 7 
study III also included 44 healthy controls 19.5 (19.2-19.9) yrs 
Methods 
• Dual energy X-ray absorptiometry (DXA) 
was performed with a Hologic QDR-2000 (Hologic inc., Waltham, Massachusetts, 
USA), (paper I and II) and Lunar Prodigy (GE Healthcare, Diegem, Belgium) 
equipment (paper III), measuring BMD (gr/cm2) at LS and FN. Fat mass (%) and lean 
body mass (LBM) (kg) were obtained and compared with healthy individuals from the 
literature. The coefficient of variation (CV) with spine phantom measurements in the 
Hologic 2000 during the period 1996 to year 2000 was 0.48%. The CV of the Lunar 
measurements ranged from 0.5% to 0.9%. 
DXA also provides t-score and z-score. As both adults and children were included in 
the investigations we used z-score to determine osteopenia and osteoporosis, although 
they were originally defined for t-scores. Reference values were given by the 
manufactures except for FN for children 9-19 years, which were obtained from the 
literature (Bachrach et al. 1999). 
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• Peripheral Quantitative Computerized Tomography (pQCT) 
A pQCT device (XCT-2000, Stratec Medizintechnik, GmbH, Pforzheim, Germany) 
was used to measure the cortical volumetric BMD (vBMD; mg/cm3), cortical BMC 
(mg/mm), cortical cross sectional area (CSA, mm2) and cortical thickness (mm) and 
trabecular and total vBMD in tibia and radius. Bone length was measured from the 
medial malleolus to the medial condyle, and forearm length was defined as the distance 
from the olecranon to the ulnar styloid process. The CVs were less than 1% for all 
pQCT measurements (paper III). 
• UVB radiation was obtained by three UVB TL 12/40W light tubes (Corona II) (fig. 7) 
(ESSHÅ Elagentur, Värnamo, Sweden) placed at a distance of 50 cm above the body 
surface. The irradiance of the units averaged 1.0 mW/cm2, measured with an IL1350 
photometer. The intensity of radiation did not change between baseline and 6 months 
as checked at randomised measures of the lamps (paper IV). 
Fig 7. UVB lamp ( Corona II) 
• Height, weight and BMI (kg/m2) were related to Swedish standards with z-score 
(Karlberg J et al. 2001, Karlberg P et al. 1976, Wilhelmsson et al. 1997), (paper I & 
II). 
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Spirometry was performed with Jaeger spirometer and the results related to the 
Swedish and European populations (Solymar et al. 1980, Quanjer et al. 1993) (paper I-
IV). 
Working capacity was determined with bicycle ergometer to a pulse frequency of > 
180/minute and compared with reference values from the literature (Nordenfeldt et al. 
1985, Godfrey et al. 1971). The working capacity was related to height and gender in 
the children and to weight, age and gender in the adults (paper 1 & II). 
Metabolic rate was measured by indirect calorimetry and expressed in relation to the 
upper normal reference values from Harrison & Benedict (Boothby & Dubois, 1954), 
i.e. a value of 1 = + 2SD of reference values (paper I ). 
Dietary records were performed prospectively for three or four days and the intake 
calculated in the PC program "DIETIST" and the values expressed in relation to the 
Nordic Nutrition Recommendations (NNR) (Nordic Nutrition Recommendations. 
1996) (paper I & IV). 
Blood samples were drawn and used for analyses according to routine. Reference 
values were obtained from the laboratory (paper I - IV). 
The number of intravenous antibiotic courses (ivAC) per year was registered (paper 
II). 
Hand grip strength was measured with JAMAR® hydraulic hand dynamometer 
(Sammons Preston Rolyan, Jackson, Illinois). Each hand was tested three times and the 
best of the three measurements were used (paper III). 
A standardized questionnaire was used to collect information about current and 
previous medication, weight bearing physical activity (hours/week, duration in years) 
and nutritional intake (dairy products, vegetables and vitamin intake). Puberty entry 
was noted by a self-assessment enquiry (early, similar or late compared to school 
mates) (paper III). 
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• Statistical analyses were performed with Student's t-test, one sample t-test and paired 
t-test at normal distribution of data, otherwise with non-parametric tests as Mann-
Whitney's U-test and Wilcoxon paired sign rank test. Spearman rank test, univariate, 
multiple and partial regression analysis were used for correlation tests. Mantel's test 
was used for testing correlations between FN z-score and age with elimination of the 
influence of gender (paper II). To test for group differences in vitamin D over time, we 
have used repeated-measures analysis of variance (ANOVA) with the Bonferroni/Dunn 
correction. Chi-square test was performed when comparing the subjects in the 
intervention and control groups for Pseudomonas, liver disease and CF related diabetes 
(paper IV). Mean (SD) was used if not otherwise indicated. Statistical significant 
difference was set at p<0.05 (paper I-IV). 
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Results 
Study I 
In this cross sectional study including 70 children and adults with CF, the mean and 
median values of anthropometric and body composition data were within the normal range. 
The oral intake of energy, calcium and vitamin D were normal compared to NNR. 
Metabolic rate was high as expected for patients with CF. Pulmonary function and working 
capacity were well preserved in most patients despite a high colonisation rate of Ps. 
aeruginosa in sputum. Serum levels of calcium and phosphate and calcitonin were all 
normal but 16 patients had 25(OH)D vitamin levels below 20 ng/ml, considered 
insufficient according to Elkin et al. (2001). 
Almost 40 % of the patients had low BMD z-score (<-lSD) in LS and/or in FN. 
Osteoporosis was rare and only seen in four patients. Strong correlation was seen between 
LS z-score and weight and height in the children but this correlation disappeared when 
adjusted for age, calcitonin and FEVi.o % in the whole group. FN z-score was related to 
weight but the correlation was stronger and independently to pulmonary function and 
working capacity. No correlations were found to serum levels or intake of vitamin D and 
calcium. 
Study II 
In a two year prospective study of 54 patients with normal anthropometric data the z-scores 
of BMD did not change during the two years. Pulmonary function and working capacity 
showed similar results as in study I. 
All biochemical values had means or medians within the normal range, but the 25(OH)D 
vitamin level was below 20 ng/ml in 16 patients. PTH levels were in the higher normal 
range. 
Forty-one and 35 % of the patients had decreased BMD z-score of LS at baseline and 
follow up, respectively, and 33% of the patients had decreased BMD z-score of FN at both 
investigations. FN z-score was lower in patients homozygous for dF508 and those who 
carried the 394delTT mutation compared with patients heterozygous for dF508 (p=0.02 for 
each). No correlations were observed with serum levels of vitamin D or calcium. 
Anthropometric and Spirometrie variables were independently of importance for the LS 
BMD. Furthermore, the lung function and SR were independently correlated to FN BMD. 
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The ratio between iPTH and the change in LS z-score over the two years, showed that high 
levels in the children were correlated to a positive change in BMD. On the contrary, the 
adults showed a negative correlation between high iPTH levels and the increment of BMD. 
Study III 
In this cross sectional study of our cohort of 16-25 year old young men with CF (n=14/16) 
and 42 healthy controls, we found similar anthropometric data in the groups and no 
differences in physical activity or handgrip strength. Twenty-one % of the patients with CF 
and 10% of the controls considered themselves to have a late puberty (ns). The CF patients 
consumed more dairy products and vitamin supplementation than the controls. The DXA 
did not reveal any differences in bone or LBM, but fat percentage was significantly lower 
in the CF patients with PI. Patients who were chronically colonized with Ps. aeruginosa 
had significantly lower total BMC and BMD in the LS than controls.The pQCT showed 
similar values in the two cohorts in all bone parameters except for trabecular BMD in the 
tibia (p=0.04). However, this difference disappeared after adjustment for age and weight. 
When dividing the CF group in patients colonized and non- colonized with Ps. aeruginosa, 
the colonized patients had lower cortical BMC and bone area in both radius and tibia and 
cortical thickness and trabecular BMD of the tibia. There were similar correlations in the 
patients and controls between body composition and bone. Multiple regression analysis 
showed that LBM was stronger correlated than BMI to bone mass. However, in patients 
with CF the strongest predictor for cortical BMC was lung function. 
Study IV 
This was an intervention study of UVB radiation in 30 patients with CF over the six dark 
winter months. The patients were divided into intervention and control groups, matched by 
age and gender. No significant differences in clinical data between the two groups were 
obtained. The nutritional intake was within the normal recommended levels (NNR). In the 
intervention group there were only 9 patients that completed the study. The adherence to 
the treatment program varied both in frequency and time, but still all patients in the 
experimental group significantly increased their vitamin D levels in serum (ANOVA 
pcO.OOOl for 25(OH)D and p=0.01 for l,25(OH)2D). The serum level of iPTH did not 
decrease in the intervention group but the serum osteocalcin decreased (pcO.OOl) over the 
study period. Frequency of exposure times rather than duration of exposure seemed to be 
of importance for the observed increase in vitamin D levels. 
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Discussion 
Clinical data and anthropometric status 
The patients with CF had a normal growth, since the mean and median z-scores for weight, 
height and BMI were normal (paper I & II). The adult patients had a lower z-score for 
height compared to children (p<0.05), but still not significantly different from the normals 
(paper II), mean (SD) being -0.5(0.9) SDS. This might be due to the fact that they had not 
had centralized treatment since early childhood, since the CF center was not established in 
Göteborg before 1992. Over the two-year study the z-scores for height and weight 
increased significantly in adults (p<0.05 and 0.02, respectively) (paper II), maybe 
reflecting a later catch up depending on late puberty and/or improved care. The 
anthropometric data in the small young male CF cohort (18-25 yrs) (paper III) was similar 
to controls suggesting that there is a possibility to achieve normal or close to normal final 
height and weight. Along with an improved general treatment, the survival has improved 
considerably and the improved height in children may be a reflection of our treatment 
policy (Blomquist et al. 1986, Lannefors et al. 2004, Strandvik 1988 & 1995). 
Mean LBM measured by DXA were normal both in children and adults compared to 
healthy controls but fat mass was lower in young CF men with PI compared to healthy 
controls (paper III). This is in contrast to several other studies, which have reported low 
LBM and muscle strength in CF patients, even in some patients with normal BMI (Bolton 
et al. 2003, Elkin et al. 2000, Ionescu et al. 2003, Sood et al. 2003). Also muscle strength 
was normal in our young adult patients (study III, Sahlberg et al 2005), as illustrated by 
normal hand grip strength compared to controls. 
LBM was strongly correlated to BMD (Crabtree et al. 2004), which we also could confirm 
(paper III). Sood et al. (2003) found that LBM decreased with age, which is in agreement 
with normal senescence but three decades too early in patients with CF. Pedreira et al. 
(2005) reported that in a group of children with CF the pulmonary function was associated 
with both BMI and LBM. That was also found by Ionescu et al. (2003) in adult patients. 
One of our patients, the outlier in study III, had low LBM, low lung function, low BMI and 
osteoporosis in accordance with the results of previous studies. On the contrary, on average 
all our patients had normal LBM (I-III) and relatively well preserved lung function. This 
might be the result of our policy to encourage physical activity from a very early age and 
use early aggressive antibiotic treatment at mild symptoms of infection. 
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Since the patients were not selected, they were representative for the CF patients in our 
cohort of Swedish patients. Compared to what has been reported in the literature, our 
population had better anthropometric data and lung function, which may explain our better 
BMD (Aris et al. 2004, Bachrach et al. 1994, Bhudhikanok et al. 1996, Conway et al. 2000, 
Elkin et al. 2001, Fok et al. 2002, Flohr et al. 2002, Gibbens et al. 1988, Haworth et 
alA999, Lambert 2000, Ott 1998, Rossini et al 2004). Fractures and kyphosis were rarely 
seen in our population, which is different from most other studies (Aris et al. 1998, 
Hendersson et al. 1994). 
Bone mineral density. 
About 40 % of the patients had decreased BMD z-score in the LS and FN at baseline and 
follow up (paper 1 & II). Osteoporosis was rare and a z-score of BMD below -2.5SD was 
seen in only four patients. All three patients with FN z-score less than -2.5 SD were on 
inhaled steroids since approximately 2 yrs. Corticosteroid therapy suppresses osteoblast 
maturation and activity and activates the osteoclast, leading to reduced bone formation and 
accelerated bone loss. Many studies (Aris et al. 1998, Conway et al. 2000, Elkin et al. 
2001, Haworth et al. 2002, Ott et al. 1998 ) have found glucocorticosteroids to be a risk 
factor for bone mass in CF. Chronic glucocorticosteroid use in children can lead to 
impaired linear growth, delayed puberty and interruption of the normal acquisition of bone 
mass, which is probably one part of the causes in many studies. An estimated 20-50 % of 
individuals with CF, worldwide are treated intermittently with glucocorticosteroids. We 
have a restrictive policy concerning the use of corticosteroids at our centre. Thus, there 
were too few patients on corticosteroid treatment to enable an analysis of the possible 
relationship between BMD and corticosteroid treatment. 
The mean and median annual change in BMD in adults was normal, i.e not different from 
zero. Most children had a very good annual growth in opposite to most previous reports, 
which found that bone accretion was reduced in patients before reaching peak bone mass 
and also an accelerated rate of bone loss thereafter (Bhudikanok et al. 1998, Haworth et al. 
2002, Ujhelyi et al. 2004). Longitudinal studies with data on growth and bone accrual in 
patients with CF are limited. The majority of the reports found high prevalence of low 
bone mass in adults but data from the adult and pediatric studies suggests that low BMD 
results from inadequate bone acquisition during puberty. Comparing our group of CF 
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patients (n=8), aged 13-16 yrs, with the result of Sundberg et al. 2001, the BMD growth 
rate was in agreement with what he found in healthy Swedish children (fig. 8) (paper II). 
Despite this positive development, the average median z-scores were reduced in both LS 
and FN in children and adults with CF, without significant improvements after two years. 
Although these results were obtained from a small group of patients, they suggest that 
impairment of BMD in CF probably starts early in life. 
Controls Controls 
Figure 8. Annual percentage change in LS H and FN • in 35 patients (6-19yrs) and 8 
patients (13-16yrs) (paper II) and 84 healthy controls (13-16yrs ) (Sundberg et al. Calcif 
Tissue 2002;71:406-415). 
Correlations of BMD to clinical data 
The LS and FN BMD and the z-scores in children were correlated to z-score for height, 
weight and BMI. Correlation between LS z-score and anthropometric data were seen both 
in study I and II but not in study III. The correlations between anthropometrics and LS 
BMD were most marked in the children. Calculating partial correlation coefficients 
showed that weight and height did not have any importance for the vertebral z-score when 
adjusted for age (paper I), which might reflect the influence of growth on LS. Body weight 
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showed the strongest correlation with FN among the anthropometric variables. In study III, 
LBM was the strongest correlate to BMD. The metabolic rate was in the higher reference 
interval, which is in agreement with what has previously been reported in patients with CF 
(O'Rawe et al. 1992). There was no correlation between high metabolic rate and low body 
weight or BMD z-score in LS (fig. 9) and in FN. 
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Figure 9. Metabolic rate in 63 CF patients (33 male) in relation to LS BMD z-score o= 
within 1 SD of the reference values for age matched controls, • > 1 SD below age matched 
controls, A > 2.5 SD below age matched controls 
There were no differences in the z-scores for BMD of LS and FN in children and adults 
regarding gender and pancreatic function. There was a tendency of lower LS z-score in 
young males accompanied by lower z-score for height compared to females (paper I). In 
the adults there was an inverse tendency of lower z-score in both LS and FN in females, 
although not significant. 
An abnormal bone formation and resorption was found in a CFTR-/- mice (Dif et al. 2004), 
and the dF508 mutation has been suggested to be a risk factor for reduced BMD in CF 
(King et al. 2005, Haworth et al. 1999). There was no correlation to CFTR genotypes 
except for FN BMD and z-score (study II), which showed significantly lower BMD in the 
adults homozygous for dF508 or those carrying 394delTT. These mutations are associated 
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with a more severe phenotype, and therefore these results may reflect other factors 
associated with the disease severity. This is further supported by the results in study III. In 
that study all PI patients but one (10/14) were homozygous for dF508, but no differences 
was found in BMD between those patients and those with mild mutations. 
The low z-scores for LS and FN may reflect an early impact of environmental factors or 
related to CFTR and it cannot be excluded that the relation to dF508 might reflect a 
common delineator such as essential fatty acid deficiency (EFAD), which has been shown 
to be related to genotype (Strandvik et al. 2001). Essential fatty acids (EFA) are required 
for normal growth and bone mass, and patients with CF have abnormal EFA metabolism 
with an increased turnover of arachidonic acid resulting in a decrease of l inoleic acid, the 
substrate from arachidonic acid synthesis. The prevalence of EFAD has been shown to 
increase in prepuberty (Lai et al. 2000) , a period of time usually considered to be a risk 
period for further decrease of BMD in CF patients (Aris et al. 2004). EFA have been 
shown to be of significant importance for the normal bone development in chicks and rats 
(Watkins et al. 2001) and we have also found an association between EFA status and BMD 
in patients with CF (Gronowitz et al. 2001). Kreutter et al. (1982) showed that chicks with 
EFAD had impaired calcium absorption over the intestinal mucosa. 
No influence was seen by liver disease or CF related diabetes mellitus in any of our 
studies, but the study population was too small to exclude if such possibilities may exist. 
Correlations of BMD to biochemical values 
All biochemical values (Ca, P, iPTH, calcitonin, osteocalcin, vitamin A, ALP) had means 
and medians within the normal range. The mean concentration of 1,25(OH)2D was 32.5 -
51.8 pg/ml (paper II & IV) (ref values 15-55 pg/ml) and of 25(OH)D, 21-28 ng/ml (paper 
I, II, IV) (ref values 10-65 ng/ml). Only 3% in study I and 6 % in study II of the patients 
were vitamin D deficient (25(OH)D), i.e had serum values below the reference range 
(<10ng/ml). A further 13 patients (19% in study I, 26% in study II) had values below 20 
ng/ml, which has been suggested the limit for vitamin D insufficiency (Elkin et al. 2001). 
In a mild and moderate vitamin D insufficiency circulating concentrations of 1,25 (OH)2 D 
levels are often normal or even elevated if associated with secondary hyperparathyroidism. 
Many studies have shown much lower serum levels of 25(OH)D in patients with CF 
despite supplementation. Elkin et al. (2001) reported that 36% of the patients had serum 
levels <10 ng/ml and 83% < 20 ng/ml and Haworth et al. (1999) found 22% < 10 ng/ml 
and 38% below 15 ng/ml. Since Sweden is located on higher latitude that would probably 
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reflect a better compliance or absorption of oral supplementations in our patients. Lark et 
al. (2001) have shown that adult CF patients had ergocalciferol absorption significantly 
lower than controls despite pancreatic enzyme supplementation, indicating that insufficient 
absorption is involved. That was one of the reasons why we were curious to find out if 
phototherapy was a good treatment alternative for patients with CF. Several other studies 
had shown a positive effect of UVB radiation on serum levels of vitamin D (Chuck et al. 
2001, Chel et al. 1998, Toss et al. 1982 ). We did not measure bone in this study, as 6 
months was to short time to detect significant changes in bone mass. Tangpricha et al. 
(2004) found that subjects who regularly used tanning beds with UVB had higher serum 
concentrations of vitamin D, lower PTH concentrations and higher BMD and z-scores at 
the total hip than did non tanners. 
In our study serum osteocalcin decreased in the UVB group over 6 months (<0.001) and 
this change was inversely correlated to the change in 25(OH)D levels (p<0.05) (fig. 10). 
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Fig. 10 The change in calcidiol in relation to the change in osteocalcin 
in 23 patients with CF over 6 months (paper IV). 
This may reflect a decreased bone turnover since increased osteocalcin levels are 
associated with high bone turnover and increased bone loss (Aris et al. 2002, Baroncelli et 
al. 1997). Heaney et al (2003) showed in a study of healthy individuals that calcium 
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absorption improved when 25(OH)D levels rose from a mean of 25 to 35ng/ml. They 
concluded that the lower limit of the current reference range (10-65 ng/ml) is set to low for 
serum 25(OH) vitamin D. Holick (2002) suggested that a vitamin D level of 30ng/ml is 
important for maximum bone health. 
It is not clear to what extent low vitamin D levels contribute to low BMD in CF. Haworth 
et al. (2000) and Elkin et ai (2002) have made bone biopsies and found that bone 
formation was decreased and that the osteoclast activity was increased in CF patients. By 
histomorphometry, they excluded osteomalacia as a main cause of low BMD in CF. The 
imbalance between formation and resorption was confirmed by Baroncelli et al. (1997). 
The lack of correlation in our studies between calcium and vitamin D both for intake and 
serum levels on one hand and BMD on the other, support the view that osteomalacia was 
not the main cause of decreased BMD in our patients. 
Serum calcium in our patients was normal and the intake was very high and no correlations 
to BMD were found. Aris et al. (1999) showed that adult CF patients have altered calcium 
homeostasis after an intake of a high calcium breakfast, even with pancreatic enzymes. 
Kreutter et al. (1983) showed that when chicks with EFAD were supplemented with 
linoleic acid the calcium absorption over the duodenal mucosa increased. Matsumoto et al. 
(1981) and Max et al. (1978) found that linoleic acid in the intestinal mucosa was 
increased by treatment with l,25(OH)2D. The effect of UVB radiation on osteocalcin 
might thus reflect an improvement in calcium absorption by the influence of l,25(OH)2D. 
Some CF patients had high serum iPTH values suggesting a mild secondary 
hyperparathyroidism, although the mean (SD) values for iPTH, was in the normal range 
compared to controls, being 48(16) ng/1 in the adults and 42(24) ng/1 in the children (ref. 
values are 10-65 ng/1). However, the iPTH values in the children were higher than in 
healthy children reported in the littérature (Cioffi et al. 2000, Fors et al. 2001). The iPTH 
levels in the UVB treated group did not decrease despite significant increase of vitamin D, 
which was unexpected. We confirmed the findings of Mortensen et al. (2000), who found 
iPTH levels in the higher reference range in a group of young patients with CF (8-12 yrs). 
Calcitonin was within the normal range, being 2.7 ng/1 (reference value <20 ng/1) and there 
were negative correlations to LS in children and to FN in adults (paper I). We suggest that 
PTH during adolescence and preadolescence might have an anabolic effect on bone 
mineralization and therefore the negative correlation between LS BMD during childhood 
to phosphate (paper II) and calcitonin found in paper I may support this hypothesis. The 
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hypothesis may include that in the children PTH rises because of a greater need for 
calcium and phosphate and calcitonin rises to inhibit the resorption from bone. 
All patients were supplemented with vitamin A although the diet included enough for 
adequate intake. The serum values were in the normal range which does not exclude 
hypervitaminosis. Melhus et al. (1998) showed that an excessive dietary intake of vitamin 
A was associated with reduced BMD and Michelsson et al. (2003) showed that the risk of 
fractures was highest among men with high levels of serum retinol. In our small study 
group, which represented younger patients, we did not find any correlation between 
vitamin A and BMD. All patient were supplemented with vitamin A (~ 5000 IU/day) in the 
same order of magnitude as in a previous paper by Lindblad et al. (1997). Those authors 
showed that the vitamin A supplementation did not cause increased vitamin A 
concentrations in serum or liver which may indicate impaired absorption in CF. 
Most studies show strong correlations between disease severity and BMD. The impact of 
infection on bone disease was strong in our studies (papers I- III) as in other studies (Aris 
et al. 2000, Conway et al. 2001, Haworth et al. 2004, Ionescu et al. 2000, Lambert 2000). 
A relation between genotype and inflammation was found by Augarten et al. (2004). 
The mean and median values of the infection parameters (paper II) were all within the 
normal range, reflecting that the patients were well controlled and in a stable condition. 
Nevertheless, correlations were seen between SR, ivAC and BMD in both LS and FN. If 
patients were grouped according to normal or pathological serum levels of IgG, the latter 
group showed a significant negative correlation to the increments of BMD in FN and LS. 
A similar but non-significant difference was found for SR (paper II). There was a 
significant correlation between BMD and z-scores of LS and FN and the number of ivAC 
and blood SR. In study III patients colonized with Ps. aeruginosa had lower bone mass 
compared to controls. Strong correlation were always found between lung function and 
bone parameters (Papers I-III). These findings suggest that also a low degree of 
inflammation might contribute to the low BMD. Previous studies (Ans et al. 2000, Ionescu 
et al. 2000, Lambert 2000) have found a clear relation to more severe infection in more 
severely affected patients. Differences in bone metabolism of FN and LS were suggested in 
the comparison between those patients who improved or deteriorated in BMD during the 
two years. In LS significant differences were found between these groups regarding z-
score for height (pcO.OOl) a nd infectious parameters as IgG (p<0.05) and SR (p<0.01). 
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Corresponding comparison in FN showed correlation to z-score for height (p<0.01) and 
strong relation to IgG, SR and number of ivAC (p<0.001 for each). Although our 
population was small the consistent finding of different correlations, might indicate 
different metabolism or sensitivity in LS and FN. 
Pulmonary function and working capacity were well preserved in most patients despite 
high colonization rate of Ps. aeruginosa. As has been previously reported, we also found a 
strong association between lung function and BMD, probably confirming the role of 
inflammation on bone disease in CF. FN z-score was related to Pseudomonas colonization 
(p=0.02) (paper I and III). The fact, that the low BMD starts early, indicates that 
inflammation and infection by other microorganisms might be as important. Previous 
studies have shown a markedly higher respiratory burst in vitro by Staphylococcus aureus 
compared to Ps. aeruginosa (Hollsing et al. 1987). 
Patients were in good physical condition, which is probably due to our general 
recommendations to focus on physical activity. The adherence to recommendations was 
supported by similar reports and results for patients as for healthy young men (paper III) 
and by a normal working capacity in both children and adults (paper I & II). Weight 
bearing activities benefit the skeletal apparatus. Habitual loading increases bone and when 
loading decreases, bone is lost (Marcus et al. 2001). Physical activity seems to influence 
the FN more than LS, as has also been reported by others. (Brahm et al. 1997, Marcus et al. 
2001.) 
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Summary 
Our results show that the cause of the low BMD in CF is multifactorial. The early start of 
decreased BMD and the normal bone growth indicate that genetic factors might be 
involved, There might be a direct effect of CFTR or effects by environmental factors 
indirectly related to CFTR. 
Efforts should be made to maximize bone growth during childhood and to increase and 
maintain bone density during adulthood to prevent fractures and kyphosis. This is very 
important since low bone mass is noticed early. The best approach to achieve these goals 
is a good preventive centralized care, and a treatment program with an aggressive attempt 
to maintain good nutrition, including vitamin supplementation and attention to calcium 
intake. If there are difficulties to preserve a good vitamin D status, artificial UVB 
irradiation may be an alternative treatment. Furthermore EFA are required for normal 
growth and bone mass and some patients may need EFA supplementation. Our studies 
showed a strong impact of infection on bone disease. An aggressive antibiotic strategy, 
involving prescriptions of short courses of high doses of antibiotics in patients with very 
mild symptoms, is very important to reduce the effect of cytokines on bone resorption. 
Weight bearing physical activity, especially before puberty, is beneficial to increase peak 
bone mass and muscle strength and also to increase the lung capacity. Corticosteroids 
should be minimized as several studies have shown corticosteroids to have a strong 
negative influence on bone mass. Bone health of adults partly reflects the preventive care 
in childhood. The results suggest differences in the impact of inflammation on LS and FN 
and illustrate the complexity of the bone mass homeostasis in CF, indicating a need for 
longitudinal prospective studies from early childhood into adult life. 
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Conclusion 
® In West Sweden almost 40% of the CF population had decreased BMD (<1SD BMD z-
score) whereas osteoporosis (<2.5SD BMD z-score) was rare. 
• Weight, height, BMI and lung function were related to low BMD. 
® Differences in sensitivity for infection and inflammatory markers and anthropometric 
data were found in BMD of LS and FN. 
• Patients with CF had normal annual accretion of bone mass during 2 years. 
• Young men with severe CF genotype and classical phenotype, who have reached their 
final height, had normal bone mass compared to healthy controls. 
• Serum levels of vitamin D in patients with CF were improved by regular ultraviolet B 
radiation. 
• The cause of bone disease in patients with CF is multifactorial, but pulmonary function 
and infection might have the highest impact. 
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